Meiji Yasuda Asset Management Co Ltd. Takes $5.93 Million Position in Bristol Myers Squibb Company $BMY

Meiji Yasuda Asset Management Co Ltd. purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 102,981 shares of the biopharmaceutical company’s stock, valued at approximately $5,934,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Te Ahumairangi Investment Management Ltd acquired a new stake in shares of Bristol Myers Squibb during the second quarter valued at about $4,593,000. Haverford Trust Co acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $2,358,000. Clear Harbor Asset Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $690,000. Davis Asset Management L.P. acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at approximately $27,000. Finally, First Nebraska Trust Co acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at approximately $628,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.1%

Shares of NYSE:BMY opened at $67.06 on Monday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company’s 50 day moving average is $60.55 and its two-hundred day moving average is $59.39. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company has a market cap of $136.98 billion, a PE ratio of 14.77, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Analyst Ratings Changes

A number of research analysts have commented on the company. Royal Bank Of Canada upped their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Truist Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Bank of America lowered their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Finally, Piper Sandler initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $66.06.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.